Lemaitre Vascular Raises Q2 Guidance, Defying Analyst Consensus

Forward-Looking Analysis

Wall Street consensus estimates for Lemaitre Vascular’s Q2 2026 earnings project an EPS of $0.70 to $0.81, with a specific company guidance range of $0.79 to $0.84 per share. This guidance significantly exceeds the initial analyst consensus of $0.75, indicating strong management confidence. Revenue is forecasted between $70.5 million and $72.5 million, aligning closely with the average analyst estimate of $71.5 million. For the full fiscal year 2026, analysts anticipate total revenues of approximately $279.8 million and EPS of $2.97 to $3.08, reflecting a steady growth trajectory. Analysts have upgraded their 2026 revenue forecasts by 9.2% year-over-year. While the company’s earnings growth forecast of 9.07% trails the broader US market’s 32.94% and industry average of 28.25%, it outperforms the medical instruments industry’s revenue growth expectation of 8.5%. The average 12-month price target stands at $117.00, suggesting a potential upside of 15.48% from current levels, with a consensus rating of "Buy" among four covering analysts. Despite a Zacks Rank of #3 (Hold), the trend of positive earnings estimate revisions supports a favorable near-term outlook.

Historical Performance Review

Lemaitre Vascular demonstrated robust momentum in Q1 2026, delivering an EPS of $0.68 that surpassed the $0.66 consensus by 2.52%, marking the fourth consecutive quarter of beating estimates. Revenue reached $66.55 million, slightly missing the $66.67 million forecast but representing an 11.1% year-over-year increase. Net income stood at $15.68 million, with gross profit reported at $48.40 million. The stock has surged approximately 37.5% year-to-date, significantly outpacing the S&P 500’s 5.2% gain. Management’s consistent ability to exceed earnings expectations, combined with raised guidance for Q2, underscores the company’s operational efficiency and strong market position within the vascular device sector.

Additional News

Lemaitre Vascular continues to focus on the design, marketing, and technical support of medical devices for peripheral vascular disease treatment. Key products include balloon catheters, carotid shunts, biologic patches, and vascular grafts. The company maintains a mid-capitalization status with a market cap of $2.11 billion. Recent market activity shows LMAT trading near its 200-day simple moving average, with shares rising 2.8% to close at $110 following Q1 results. Analysts have updated their earnings models post-Q1, raising the consensus price target by 6.2% to $118. The company has issued 31 guidance updates since October 2022, raising its outlook 17 times, which signals evolving management expectations. No significant M&A activity or CEO changes were reported in the provided data.

Summary & Outlook

Lemaitre Vascular exhibits strong financial health, evidenced by consistent earnings beats and raised guidance for Q2 2026. The company is well-positioned for growth, with revenue forecast to outpace its industry peers, although earnings growth lags the broader market. Key catalysts include its expanding product portfolio in vascular disease treatment and management’s history of optimistic guidance revisions. Risks include slower earnings growth relative to the tech-driven market and a high P/E ratio of 37.39. Overall, the outlook is cautiously bullish, supported by solid operational performance and analyst upgrades, though investors should monitor the sustainability of growth rates amid broader market volatility.